XKRX
002390
Market cap110mUSD
Dec 05, Last price
11,860.00KRW
1D
-0.25%
1Q
0.59%
Jan 2017
-54.82%
Name
Handok Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||